Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adultsM.L. Piel-Julian, L. Prudhomme, Matthieu Mahévas et al.|Journal of Thrombosis and Haemostasis|2018Cited by 138
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic riskJill Corre, Hervé Avet‐Loiseau, Sabine Bréchignac et al.|Haematologica|2019Cited by 90
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Cyrille Touzeau et al.|Blood|2025Cited by 34
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Marguerite Vignon, Valérie Lauwers‐Cancès et al.|Blood|2022Cited by 25
Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple MyelomaStéphanie Guidez, Xavier Leleu, Guillemette Fouquet et al.|Blood|2015Cited by 0